AzTrials
AzTrials

Paroxysmal Nocturnal HemoglobinuriaPhase 2NCT05476887

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104

A Phase 2 study testing KP104 in people with Paroxysmal Nocturnal Hemoglobinuria, run by Kira Pharmacenticals (US), LLC. at 4 sites in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in complement inhibitor-naïve participants with PNH. The study will be conducted in 2 parts. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Paroxysmal Nocturnal Hemoglobinuria
What is being tested?
KP104
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
35 participants
Where
4 sitesChina
Study dates
25 Nov 2022to Feb 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Initial Treatment Period:
  • Documented diagnosis of PNH confirmed by flow cytometry evaluation of white blood cells and red blood cells, with granulocyte or monocyte clone size of >= 10 percent (%) within 6 months of the Screening visit.
  • Presence of 1 or more PNH-related signs or symptoms within 3 months of initiation of Screening.
  • LDH >= 2.0 × upper limit of normal (ULN) at screening.
  • Hemoglobin <= 10.0 g/dL at screening.
  • Females of childbearing potential and males must practice effective contraception from Screening until 28 days after the end of study (EOS) visit.
Show all 11Show fewer
  • Females of childbearing potential must have a negative pregnancy test at Screening and within 24 hours prior to dosing of study drug.
  • Extension Treatment Period (OLE):
  • Complete the 12-week (weekly dosing) or 13-week (biweekly dosing) Initial Treatment Period per the protocol.
  • Benefited from KP104 treatment and will continue benefiting from KP104 treatment per the investigator's judgement.
  • Willing to participate in Extension Treatment Period, able to comply with this protocol and be available for the entire duration of the study.

Who cannot join

  • Initial Treatment Period:
  • Any clinically significant poorly controlled underlying illness other than PNH per discretion of investigators.
  • Treatment of any infection with IV (within 30 days of Screening) or oral (within 14 days of Screening) antibiotics, antivirals, or antifungals.
  • History of meningococcal infection.
  • History of untreated tuberculosis.
  • History of splenectomy
Show all 18Show fewer
  • Positive serology for Hepatitis C Virus (HCV) ribonucleic acid (RNA) or human immunodeficiency virus (HIV) at Screening
  • History of bone marrow or stem cell transplantation
  • Absolute neutrophil count (ANC) <500 cells per microliter (cells/μL)
  • Reticulocyte count< 100 x 10^3 cells/μL
  • Platelet count< 30,000 cells/μL
  • History of systemic autoimmune disease
  • Estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 meter square (mL/min/1.73 m^2) calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
  • Extension Treatment Period (OLE):
  • Women who are pregnant.
  • Women of childbearing potential and men with sexual partners of childbearing potential who are not using adequate contraception and who are not willing to use adequate contraception.
  • Any medical condition that, in the opinion of the investigator, may pose a safety risk to a participant in this study, or may interfere with study participation.
  • Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

4 sites in 1 country.

China4 sites

  • Peking Union Medical College Hospital

    Beijing

  • Jiangsu Province Hospital

    Nanjing

  • Chinese Academy of Medical Sciences Peking Union Medical College - Institute of Hematology Blood Diseases Hospital

    Tianjin

  • Henan Cancer Hospital

    Zhengzhou

Other trials in China

About this study

Official title: An Open-label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-naïve Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in complement inhibitor-naïve participants with PNH. The study will be conducted in 2 parts. Part 1 is a dose-selection study to assess escalating doses and varying dose intervals of KP104. Part 2 is a proof-of-concept (POC) study assessing the efficacy of the optimal intravenous (IV) loading dose followed by the optimal maintenance dose and regimen of KP104. Participants who complete the Initial Treatment Period and demonstrate benefit from KP104 will be eligible for a 9-month open-label extension (OLE) treatment period.

Being tested
KP104
Keywords
KP104, Paroxysmal nocturnal hemoglobinuria, Complement Inhibitor, Dose Selection, Proof of Concept
Medical subject headings
Hemoglobinuria, Paroxysmal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • KP104Drug

    KP104 intravenously (IV loading + subcutaneous [SC] maintenance every week [QW] or every 2 weeks [Q2W]) will be administered.

Study groups in NCT05476887
Study groupRoleWhat they receive
Part 1: Dose escalation Cohort 1ExperimentalParticipants will receive escalating and varying dose intervals of KP104 every week.
Receives: Drug: KP104
Part 1: Dose escalation Cohort 2ExperimentalParticipants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
Receives: Drug: KP104
Part 1: Dose escalation Cohort 3ExperimentalParticipants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
Receives: Drug: KP104
Part 2: Proof-of-concept Cohort 1ExperimentalParticipants will receive escalating and varying dose intervals of KP104 weekly or biweekly.
Receives: Drug: KP104
Open-label extension (OLE)ExperimentalParticipants will receive KP104, who benefit from KP104 treatment in Part 1 and 2
Receives: Drug: KP104

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part 1: Number of participants with Dose-limiting toxicities (DLT)

    A DLT is defined as any adverse event considered by the investigator to be KP104-related with a severity greater than or equal to (>=) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 3 which also represents a shift from baseline clinical status of > 1 NCI CTCAE grade. A hypersensitivity/administration reaction occurring with a severity of Grade 2 despite the use of pre-medications will also be designated as a DLT.

    Measured: Up to Week 4

  2. Part 2: Percentage of participants with >= 2 grams per deciliter (g/dL) increase in hemoglobin level from Baseline in the absence of transfusion for weekly dosing

    Blood samples will be collected for the analysis of increase in hemoglobin levels in the absence of transfusion.

    Measured: Baseline and at Week 12

  3. Part 2: Percentage of participants with >= 2 g/dL increase in hemoglobin level from Baseline in the absence of transfusion for biweekly dosing

    Blood samples will be collected for the analysis of increase in hemoglobin levels in the absence of transfusion.

    Measured: Baseline and at Week 13

  4. Open-label Extension (OLE): Number of participants reporting Treatment Emergent Adverse Events (TEAEs), treatment-emergent serious adverse events (TESAEs) and AEs of special interest (AESIs)

    Measured: Up to 9 months

Secondary outcomes (9)

  1. Part 2: Change from Baseline in serum lactate dehydrogenase (LDH) levels for weekly dosing

    Blood samples will be collected for the analysis of serum LDH.

    Measured: Baseline and at Week 12

  2. Part 2: Change from Baseline in serum LDH levels for biweekly dosing

    Blood samples will be collected for the analysis of serum LDH.

    Measured: Baseline and at Week 13

  3. Part 2: Change from Baseline in hemoglobin level for weekly dosing

    Blood samples will be collected for the analysis of hemoglobin level

    Measured: Baseline and at Week 12

  4. Part 2: Change from Baseline in the hemoglobin level for biweekly dosing

    Blood samples will be collected for the analysis of hemoglobin level.

    Measured: Baseline and at Week 13

  5. Part 2: Change from Baseline in red blood cell (RBC) transfusion dependence for weekly dosing

    The RBC transfusion dependence is the difference in the volume of RBC transfusions per month for the 3 months prior to initiation of investigational product versus the volume of RBC transfusions per month for each month on study.

    Measured: Baseline and at Week 12

  6. Part 2: Change in RBC transfusion dependence for biweekly dosing

    The RBC transfusion difference is the difference in the volume of RBC transfusions per month for the 3 months prior to initiation of investigational product versus the volume of RBC transfusions per month for each month on study.

    Measured: Baseline and at Week 13

  7. Part 1 and 2: Number of participants reporting TEAEs, TESAEs and AESIs

    Measured: Up to Week 13

  8. Part 1 and 2: Concentration within one hour of end of infusion (CEOI) of KP104

    Measured: Up to Week 13

  9. Part 1 and 2: Trough concentration (Ctrough) of KP104

    Measured: Up to Week 13

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jul 2022
  2. Study start25 Nov 2022
  3. Primary completionNov 2024 (estimated)
  4. Study completionFeb 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
35 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05476887
Sponsor's protocol ID
KP104-201
Status last verified
Oct 2024
First submitted
25 Jul 2022
Last updated
28 Oct 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing KP104 in people with Paroxysmal Nocturnal Hemoglobinuria, run by Kira Pharmacenticals (US), LLC. at 4 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part 1: Number of participants with Dose-limiting toxicities (DLT) (time frame: Up to Week 4). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05476887.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in